Form 4: Vaxcyte Executive Boosts Stake with RSU Grant, Option Exercise

Vaxcyte's SVP of Finance and CAO, Elvia Cowan, reported significant equity transactions, including RSU grants and stock option exercises.

Summary

• Elvia Cowan, SVP, Finance & CAO of Vaxcyte, Inc. (PCVX), acquired 10,681 shares of Common Stock through Restricted Stock Units (RSUs) on February 26, 2026, at a price of $0.
• Cowan also exercised stock options to acquire 7,716 shares of Common Stock at an exercise price of $25.92 on February 26, 2026.
• To cover applicable tax withholding obligations realized upon the vesting of RSUs, Cowan disposed of 243 shares on February 28, 2026, and an additional 326 shares on March 2, 2026, both at a price of $61.98 per share.
• A new grant of 17,855 stock options with an exercise price of $60 was reported on February 26, 2026, with vesting scheduled monthly over 48 months starting March 26, 2026.
• Following these transactions, Cowan beneficially owns 31,362 shares of Common Stock and 17,855 newly granted stock options, in addition to 98,568 previously held stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the executive is increasing their equity stake through grants and exercises, indicating continued commitment and alignment with company performance, despite some shares being sold for tax purposes.

Positives

• Acquisition of 10,681 shares through an RSU grant, indicating continued equity incentive and alignment with company performance.
• Exercise of 7,716 stock options, converting derivative securities into direct stock ownership.
• Grant of 17,855 new stock options, further aligning executive interests with Vaxcyte's long-term growth and shareholder value.

Negatives

• Disposal of a total of 569 shares (243 shares on February 28, 2026, and 326 shares on March 2, 2026) to cover tax withholding obligations, resulting in a reduction of direct share ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, such as RSU grants and option exercises, are common forms of executive compensation in the biotechnology and pharmaceutical sectors, aligning management incentives with shareholder value creation. The grant of new equity awards suggests continued confidence in the executive's role and the company's future prospects.

Stakeholder Impact

• Shareholders: The transactions demonstrate continued alignment of executive interests with shareholder value through equity grants and exercises, potentially fostering confidence in management's long-term commitment.
• Employees: Standard executive compensation practices, including RSU and option grants, may signal stability and the continuation of incentive programs within the company.

Next Steps

• RSUs will vest as to 1/4 of the shares on September 7, 2026, and 1/8 every six months thereafter, subject to continuous service.
• Newly granted stock options will vest 1/48 monthly, starting March 26, 2026, subject to continuous service.
• Previously held stock options continue to vest monthly, subject to continuous service.

Key Dates

Recommendation

The Form 4 filing details routine executive compensation activities, including RSU grants and option exercises, which are generally positive for aligning management incentives. However, it does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment thesis. The transactions reflect standard practice rather than a strong buy or sell signal based solely on this filing.

Keywords

Vaxcyte, PCVX, Elvia Cowan, insider transaction, Form 4, RSU, stock option, equity grant, executive compensation, beneficial ownership